Osteoporos Int: 小心使用!抗组胺药可能增加老年人伤害性跌倒或骨折风险

2018-11-25 吴星 环球医学

尽管具有抗胆碱能副作用,但一代抗组胺药广泛用于老年患者。2018年10月,韩国学者发表在《Osteoporos Int》的一项系统评价和Meta分析,考察了抗组胺药的使用是否增加老年人伤害性跌倒或骨折风险。

尽管具有抗胆碱能副作用,但一代抗组胺药广泛用于老年患者。2018年10月,韩国学者发表在《Osteoporos Int》的一项系统评价和Meta分析,考察了抗组胺药的使用是否增加老年人伤害性跌倒或骨折风险。

介绍:一代抗组胺药由于其具有抗胆碱能副作用而被认为可能不适用于老年患者。研究者旨在确定服用抗组胺药的老年患者伤害性跌倒或骨折风险是否增加。

方法:研究者鉴别出截至2016年11月的MEDLINE、EMBASE和几个当地数据库的研究。研究者选择了调查抗组胺药使用和伤害性跌倒或骨折风险相关性的观察性研究。评估了研究质量和证据水平。随机效应模型用于Meta分析,基于I2和Cochrane Q检验检测异质性。当不能解释各研究的异质性时,进行亚组分析。

结果:鉴别出的473项研究中,基于入组标准,5项(3项病例对照研究,1项队列研究,1项病例交叉研究)纳入到分析中。一代抗组胺药的使用会显着增加伤害性跌倒或骨折风险(比值比[OR],2.03;95% 置信区间[CI],1.49~2.76;异质性p=0.41;I2=0%)。包括所有代抗组胺药或未包含哪代抗组胺药信息的研究都考察了住院期间的跌倒。这些研究中,该相关性为统计学显着性,但无异质性(OR,2.89;95% CI,1.71~4.89;异质性p=0.42;I2=0%)。由于纳入的研究数量较少,以及未调整的结果,基于亚组分析的有意义的结论有限。

结论:一代抗组胺药的使用与老人伤害性跌倒和骨折风险的增加可能显着相关。当为老年患者处方一代抗组胺药时,医生需要谨慎。

原始出处:

Cho H, Myung J, Suh HS, et al. Antihistamine use and the risk of injurious falls or fracture in elderly patients: a systematic review and meta-analysis. Osteoporos Int. 2018 Oct;29(10):2163-2170. doi: 10.1007/s00198-018-4564-z.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1742154, encodeId=177d1e42154b9, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Tue Apr 02 14:41:00 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311572, encodeId=d47e13115e24e, content=<a href='/topic/show?id=b53e5560953' target=_blank style='color:#2F92EE;'>#抗组胺药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55609, encryptionId=b53e5560953, topicName=抗组胺药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Nov 27 00:41:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364421, encodeId=c1ee1364421e9, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Nov 27 00:41:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390399, encodeId=82dd13903995d, content=<a href='/topic/show?id=22c6101695c9' target=_blank style='color:#2F92EE;'>#骨折风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101695, encryptionId=22c6101695c9, topicName=骨折风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Tue Nov 27 00:41:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353615, encodeId=05c735361519, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Nov 25 09:57:29 CST 2018, time=2018-11-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1742154, encodeId=177d1e42154b9, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Tue Apr 02 14:41:00 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311572, encodeId=d47e13115e24e, content=<a href='/topic/show?id=b53e5560953' target=_blank style='color:#2F92EE;'>#抗组胺药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55609, encryptionId=b53e5560953, topicName=抗组胺药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Nov 27 00:41:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364421, encodeId=c1ee1364421e9, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Nov 27 00:41:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390399, encodeId=82dd13903995d, content=<a href='/topic/show?id=22c6101695c9' target=_blank style='color:#2F92EE;'>#骨折风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101695, encryptionId=22c6101695c9, topicName=骨折风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Tue Nov 27 00:41:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353615, encodeId=05c735361519, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Nov 25 09:57:29 CST 2018, time=2018-11-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1742154, encodeId=177d1e42154b9, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Tue Apr 02 14:41:00 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311572, encodeId=d47e13115e24e, content=<a href='/topic/show?id=b53e5560953' target=_blank style='color:#2F92EE;'>#抗组胺药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55609, encryptionId=b53e5560953, topicName=抗组胺药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Nov 27 00:41:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364421, encodeId=c1ee1364421e9, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Nov 27 00:41:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390399, encodeId=82dd13903995d, content=<a href='/topic/show?id=22c6101695c9' target=_blank style='color:#2F92EE;'>#骨折风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101695, encryptionId=22c6101695c9, topicName=骨折风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Tue Nov 27 00:41:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353615, encodeId=05c735361519, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Nov 25 09:57:29 CST 2018, time=2018-11-25, status=1, ipAttribution=)]
    2018-11-27 lsndxfj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1742154, encodeId=177d1e42154b9, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Tue Apr 02 14:41:00 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311572, encodeId=d47e13115e24e, content=<a href='/topic/show?id=b53e5560953' target=_blank style='color:#2F92EE;'>#抗组胺药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55609, encryptionId=b53e5560953, topicName=抗组胺药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Nov 27 00:41:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364421, encodeId=c1ee1364421e9, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Nov 27 00:41:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390399, encodeId=82dd13903995d, content=<a href='/topic/show?id=22c6101695c9' target=_blank style='color:#2F92EE;'>#骨折风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101695, encryptionId=22c6101695c9, topicName=骨折风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Tue Nov 27 00:41:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353615, encodeId=05c735361519, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Nov 25 09:57:29 CST 2018, time=2018-11-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1742154, encodeId=177d1e42154b9, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Tue Apr 02 14:41:00 CST 2019, time=2019-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311572, encodeId=d47e13115e24e, content=<a href='/topic/show?id=b53e5560953' target=_blank style='color:#2F92EE;'>#抗组胺药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55609, encryptionId=b53e5560953, topicName=抗组胺药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Nov 27 00:41:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364421, encodeId=c1ee1364421e9, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Nov 27 00:41:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390399, encodeId=82dd13903995d, content=<a href='/topic/show?id=22c6101695c9' target=_blank style='color:#2F92EE;'>#骨折风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101695, encryptionId=22c6101695c9, topicName=骨折风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Tue Nov 27 00:41:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353615, encodeId=05c735361519, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Nov 25 09:57:29 CST 2018, time=2018-11-25, status=1, ipAttribution=)]
    2018-11-25 医者仁心5538

    学习了

    0

相关资讯

抗组胺药在皮肤科应用专家共识

抗组胺药是皮肤科常用药,是医师处方量最大的药物之一,而且品种繁多,临床常用药物多达20多个。抗组胺药治疗哪些疾病有效?如何根据临床疾病特点选择合适的抗组胺药,以达到最佳疗效,同时又使不良反应降到最低;特殊人群如妊娠、哺乳期妇女、儿童、老年人及有肝肾损害的患者应该如何选择抗组胺药等均是皮肤科医生关注的问题。有鉴于此,中西医结合学会皮肤性病学专业委员会环境与职业性皮肤病学组组织国内部分专家对抗组胺药的

BMJ:专家不建议儿童感冒使用解充血剂、紫锥菊等药品

澳大利亚昆士兰大学全科医学博士Mieke L.van Driel在《英国医学杂志》发表的一篇社论指出,由于缺乏证据支持,且这些药物的安全性仍然不确定,不建议患普通感冒的儿童使用非处方解充血剂和抗组胺药。

抗组胺药皮肤科临床应用策略

抗组胺药是过敏性疾病的常用药物之一,对于抗组胺药的使用不少医师仍有许多困惑,比如抗组胺药可以用于哪些皮肤科疾病,如何根据患者的临床表现选择合适的抗组胺药,如何调整抗组胺药的剂量,如何联用药,如何避免延误的不良反应等。本文就以上问题做一概述。